Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto And Eylea Keep Bayer Buoyant

Despite Shadow Cast By Roundup Lawsuits

Executive Summary

The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.

You may also be interested in...



Novartis’s Beovu Launch Clouded By Safety Worries

New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.

Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141740

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel